FR15C0036I2 - Un inhibiteur de n-acylsphingosine glycosyltransferase - Google Patents

Un inhibiteur de n-acylsphingosine glycosyltransferase

Info

Publication number
FR15C0036I2
FR15C0036I2 FR15C0036C FR15C0036C FR15C0036I2 FR 15C0036 I2 FR15C0036 I2 FR 15C0036I2 FR 15C0036 C FR15C0036 C FR 15C0036C FR 15C0036 C FR15C0036 C FR 15C0036C FR 15C0036 I2 FR15C0036 I2 FR 15C0036I2
Authority
FR
France
Prior art keywords
acylsphingosine
glycosyltransferase inhibitor
glycosyltransferase
inhibitor
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR15C0036C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
University of Michigan
Original Assignee
Genzyme Corp
University of Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23182463&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR15C0036(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp, University of Michigan filed Critical Genzyme Corp
Publication of FR15C0036I1 publication Critical patent/FR15C0036I1/fr
Application granted granted Critical
Publication of FR15C0036I2 publication Critical patent/FR15C0036I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Cosmetics (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
FR15C0036C 2001-07-16 2015-05-13 Un inhibiteur de n-acylsphingosine glycosyltransferase Active FR15C0036I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30581401P 2001-07-16 2001-07-16
PCT/US2002/022659 WO2003008399A1 (en) 2001-07-16 2002-07-16 Synthesis of udp-glucose: n-acylsphingosine glucosyltransferase inhibitors

Publications (2)

Publication Number Publication Date
FR15C0036I1 FR15C0036I1 (ru) 2015-06-26
FR15C0036I2 true FR15C0036I2 (fr) 2016-05-27

Family

ID=23182463

Family Applications (1)

Application Number Title Priority Date Filing Date
FR15C0036C Active FR15C0036I2 (fr) 2001-07-16 2015-05-13 Un inhibiteur de n-acylsphingosine glycosyltransferase

Country Status (16)

Country Link
US (11) US6855830B2 (ru)
EP (3) EP2067775B1 (ru)
JP (6) JP5038582B2 (ru)
AT (2) ATE554082T1 (ru)
BE (1) BE2015C029I2 (ru)
BR (3) BRPI0211379B8 (ru)
CA (1) CA2453978C (ru)
CY (1) CY2015028I1 (ru)
DK (3) DK2067775T3 (ru)
ES (3) ES2395463T3 (ru)
FR (1) FR15C0036I2 (ru)
HK (2) HK1132267A1 (ru)
IL (3) IL159905A0 (ru)
LU (1) LU92717I2 (ru)
PT (3) PT2266968E (ru)
WO (1) WO2003008399A1 (ru)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6890949B1 (en) * 1999-07-09 2005-05-10 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
WO2002062777A2 (en) 2001-01-10 2002-08-15 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
ATE554082T1 (de) * 2001-07-16 2012-05-15 Genzyme Corp N-acetylsphingosin glukosyltransferase inhibitor
US6835831B2 (en) * 2001-11-26 2004-12-28 Genzyme Corporation Diastereoselective synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors
US6916802B2 (en) * 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
US20060217560A1 (en) * 2002-04-29 2006-09-28 Shayman James A Amino ceramide-like compounds and therapeutic methods of use
JP4195411B2 (ja) * 2004-04-12 2008-12-10 セイコーエプソン株式会社 有機エレクトロルミネッセンス装置の製造方法
US8003617B2 (en) * 2004-11-10 2011-08-23 Genzyme Corporation Methods of treating diabetes mellitus
JP5042040B2 (ja) * 2005-01-26 2012-10-03 アラーガン、インコーポレイテッド 鎮痛活性および／または免疫賦活活性を有する１−アリール−１−ヒドロキシ−２，３−ジアミノ−プロピルアミン、１−ヘテロアリール−１−ヒドロキシ−２，３−ジアミノ−プロピルアミンおよび関連化合物
PT2032134E (pt) 2006-05-09 2015-10-07 Genzyme Corp Métodos de tratamento da doença do fígado gorduroso
CN101631794B (zh) 2007-01-18 2013-01-02 建新公司 包含氨基氧基基团的寡糖及其轭合物
US20140179925A1 (en) 2009-09-04 2014-06-26 Allergan, Inc. Methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds
US9314466B2 (en) 2007-03-06 2016-04-19 Allergan, Inc. Methods for treating cognitive disorders using 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds
PT2481407T (pt) * 2007-03-06 2018-12-28 Allergan Inc Compostos para utilização no tratamento de distúrbios cognitivos
US8173683B2 (en) 2007-03-06 2012-05-08 Allergan, Inc. Methods for treating cognitive disorders
EP2594565B1 (en) 2007-05-31 2018-10-24 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitors
BRPI0823522A2 (pt) 2007-10-05 2014-01-07 Genzyme Corp Uso de um composto derivado de ceramida
US8168631B2 (en) 2008-02-05 2012-05-01 Allergan, Inc. 3-(4-fluorophenyl)-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic activity
WO2010014554A1 (en) 2008-07-28 2010-02-04 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
WO2010039256A1 (en) 2008-10-03 2010-04-08 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
BR122020010601B8 (pt) 2008-12-16 2021-07-27 Genzyme Corp conjugados de proteína-oligossacarídeo, seus usos, e composições farmacêuticas
SI3133070T1 (sl) * 2009-11-27 2019-11-29 Genzyme Corp Eliglustat (GENZ 112638) kot inhibitor sintaze glukozilceramida za uporabo v postopku zdravljenja Fabrjyeve ali Gaucherjeve bolezni, kjer postopek obsega prilagajanje individualnega terapevtskega odmerka metabolizmu P-450 pacienta
EP3236686A1 (en) 2010-04-16 2017-10-25 Kyocera Corporation Radio communication system, high-power base station, low-power base station, and communication control method
AU2012245280A1 (en) 2011-04-22 2013-11-07 Genzyme Corporation Modified acid alpha glucosidase with accelerated processing
US8961959B2 (en) 2011-10-17 2015-02-24 The Regents Of The University Of Michigan Glucosylceramide synthase inhibitors and therapeutic methods using the same
CA2906396A1 (en) 2013-03-15 2014-09-25 Concert Pharmaceuticals Inc. Inhibitors of the enzyme udp-glucose: n-acyl-sphingosine glucosyltransferase
EP3912977A1 (en) 2013-09-20 2021-11-24 BioMarin Pharmaceutical Inc. Glucosylceramide synthase inhibitors for the treatment of diseases
WO2015059679A1 (en) * 2013-10-25 2015-04-30 Dr. Reddy's Laboratories Limited Improved process for the preparation of eliglustat
WO2015065937A1 (en) 2013-10-29 2015-05-07 Biomarin Pharmaceutical Inc. N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors
ES2856898T3 (es) 2015-02-02 2021-09-28 Univ Michigan Regents Inhibidores de glucosilceramida sintasa y métodos terapéuticos que usan los mismos
CN104557851B (zh) * 2015-02-10 2017-04-05 苏州明锐医药科技有限公司 依鲁司他的制备方法
EP3283483B1 (en) 2015-04-14 2018-12-19 Sandoz AG Crystalline eliglustat hydrochloride
WO2017068496A1 (en) * 2015-10-20 2017-04-27 Dr. Reddy' S Laboratories Limited Improved process for the preparation of eliglustat and its salts
CN105646442A (zh) * 2015-10-27 2016-06-08 北京凯莱天成医药科技有限公司 一种依利格鲁司他的制备方法
WO2017178499A1 (en) 2016-04-11 2017-10-19 Spedding Research Solutions Inhibitors of glucosylceramide degradation in the treatment of diseases of the motor units
CN106349210A (zh) * 2016-08-24 2017-01-25 北京阳光诺和药物研究有限公司 一种制备酒石酸艾力骨司坦的方法
CN106967042B (zh) 2017-03-21 2020-08-14 浙江奥翔药业股份有限公司 依利格鲁司他的合成方法及其中间体化合物
CN108822072B (zh) * 2017-04-11 2021-01-12 中国医学科学院药物研究所 一种制备伊力格鲁司他的方法
WO2018193090A2 (en) 2017-04-21 2018-10-25 Amneal Pharmaceuticals Company Gmbh Process for preparation of eliglustat hemitartrate and intermediates thereof
ZA201803719B (en) 2017-06-05 2019-04-24 Cipla Ltd Stable solid dispersions of eliglustat hemitartrate
US10888544B2 (en) 2017-12-15 2021-01-12 Genzyme Corporation Methods for treating Gaucher disease
CN111217791B (zh) * 2018-11-27 2024-02-02 广东东阳光药业股份有限公司 依鲁司他中间体及其制备方法
EP3941917A4 (en) * 2019-03-22 2022-12-21 Piramal Pharma Limited IMPROVED PROCESS FOR THE PREPARATION OF ELIGLUSTAT AND ITS INTERMEDIATE
WO2020193746A1 (en) 2019-03-28 2020-10-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival of patients suffering from melanoma
US11220479B2 (en) 2019-10-23 2022-01-11 The Regents Of The University Of Michigan Glucosylceramide synthase inhibitors and therapeutic methods using the same
WO2021214771A1 (en) 2020-04-23 2021-10-28 The Israel Institute of Biological Research (IIBR) Glucosylceramide synthase inhibitors for prevention and treatment of viral diseases
US20230212123A1 (en) 2020-04-28 2023-07-06 The Regents Of The University Of Michigan Pyridine Inhibitors of Glucosylceramide Synthase and Therapeutic Methods Using the Same
CN116120274A (zh) 2021-11-12 2023-05-16 曙方(上海)医药科技有限公司 依利格鲁司他可药用盐及其晶型
EP4201403A1 (en) 2021-12-21 2023-06-28 Som Innovation Biotech, S.L. Compounds tirapazamine and quazinone for use in the treatment of gm2 gangliosidoses

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8311286D0 (en) 1983-04-26 1983-06-02 Searle & Co Carboxyalkyl peptide derivatives
DE3522475A1 (de) 1985-06-22 1987-01-02 Kali Chemie Pharma Gmbh Neue aromatische verbindungen, ihre herstellung und verwendung
JPH0416856A (ja) 1990-05-10 1992-01-21 Canon Inc 正帯電性非磁性トナー
ZA929008B (en) 1991-12-13 1993-05-21 Bristol Myers Squibb Co Piperazinyl- and piperidinyl-cyclohexanols.
CN1128951A (zh) 1993-08-13 1996-08-14 生化学工业株式会社 治疗神经元疾病的药物
ATE195944T1 (de) * 1994-02-02 2000-09-15 Liposome Co Inc Pharmazeutisch wirksame verbindungen und liposome und verfahren zu deren herstellung
AU698833B2 (en) 1994-06-10 1998-11-12 Seikagaku Corporation 2-acylaminopropanol compound and medical composition
FR2734819B1 (fr) 1995-05-31 1997-07-04 Adir Nouveaux composes de la piperazine, de la piperidine et de la 1,2,5,6-tetrahydropyridine, leur procede de preparation et les compositions pharmaceutiques les contenant
WO2001004108A1 (en) 1999-07-09 2001-01-18 Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US20030073680A1 (en) * 1995-09-20 2003-04-17 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US6255336B1 (en) 1995-09-20 2001-07-03 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US6890949B1 (en) 1999-07-09 2005-05-10 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
WO1997010817A1 (en) * 1995-09-20 1997-03-27 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
NO965193L (no) 1995-12-08 1997-06-09 Seikagaku Kogyo Kk Seikagaku C Aminalkoholderivat og fremgangsmåte for fremstilling derav
JP3993908B2 (ja) * 1995-12-08 2007-10-17 生化学工業株式会社 アミノアルコール誘導体及び該誘導体の製造方法
JP4140984B2 (ja) 1995-12-20 2008-08-27 生化学工業株式会社 分化誘導作用を有する薬剤
US5916802A (en) * 1997-02-19 1999-06-29 Fritz Berthold Device for measuring ATP
US5972928A (en) * 1997-05-21 1999-10-26 Johns Hopkins University Methods for treatment of conditions associated with lactosylceramide
JP4036500B2 (ja) 1997-05-23 2008-01-23 生化学工業株式会社 アミノアルコール誘導体及びそれを含有する医薬
JP4176170B2 (ja) 1997-06-06 2008-11-05 生化学工業株式会社 アミノアルコール誘導体を含む医薬及び異常増殖性疾患治療薬
EP1098642B1 (en) * 1998-07-27 2007-04-04 Johns Hopkins University Diamino-propanol-compounds for treating ischemia
US20020198240A1 (en) * 2001-01-10 2002-12-26 Shayman James A. Amino ceramide - like compounds and therapeutic methods of use
WO2002062777A2 (en) 2001-01-10 2002-08-15 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US7148251B2 (en) 2001-01-10 2006-12-12 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US20040260099A1 (en) 2001-01-10 2004-12-23 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
ATE554082T1 (de) 2001-07-16 2012-05-15 Genzyme Corp N-acetylsphingosin glukosyltransferase inhibitor
US6916802B2 (en) * 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
US20060217560A1 (en) 2002-04-29 2006-09-28 Shayman James A Amino ceramide-like compounds and therapeutic methods of use
PT2032134E (pt) * 2006-05-09 2015-10-07 Genzyme Corp Métodos de tratamento da doença do fígado gorduroso

Also Published As

Publication number Publication date
EP1409467A1 (en) 2004-04-21
JP2010095546A (ja) 2010-04-30
JP5038582B2 (ja) 2012-10-03
PT2266968E (pt) 2013-02-25
BRPI0211379B1 (pt) 2018-02-14
JP2005255686A (ja) 2005-09-22
US20110003987A1 (en) 2011-01-06
US7763738B2 (en) 2010-07-27
US20170334888A1 (en) 2017-11-23
US20070203223A1 (en) 2007-08-30
PT2067775E (pt) 2012-07-16
EP2266968B1 (en) 2013-01-09
JP5227348B2 (ja) 2013-07-03
US6855830B2 (en) 2005-02-15
JP2017075151A (ja) 2017-04-20
EP2266968A2 (en) 2010-12-29
US7196205B2 (en) 2007-03-27
ATE555102T1 (de) 2012-05-15
BR0211379A (pt) 2004-08-17
BR122015016314B8 (pt) 2021-05-25
ES2395122T3 (es) 2013-02-08
US20210171507A1 (en) 2021-06-10
FR15C0036I1 (ru) 2015-06-26
BR122015016313B1 (pt) 2019-04-16
HK1132267A1 (en) 2010-02-19
ES2399323T3 (es) 2013-03-27
US7615573B2 (en) 2009-11-10
IL193244A0 (en) 2009-02-11
CA2453978A1 (en) 2003-01-30
BE2015C029I2 (ru) 2021-07-19
IL159905A (en) 2009-05-04
JP2015180656A (ja) 2015-10-15
EP2067775B1 (en) 2012-04-25
CA2453978C (en) 2011-10-11
IL159905A0 (en) 2004-06-20
JP6182254B2 (ja) 2017-08-16
WO2003008399A1 (en) 2003-01-30
HK1153733A1 (ru) 2012-04-05
BRPI0211379B8 (pt) 2021-05-25
US20150148534A1 (en) 2015-05-28
BR122015016314B1 (pt) 2019-04-16
US8138353B2 (en) 2012-03-20
CY2015028I2 (el) 2016-07-27
US20030050299A1 (en) 2003-03-13
US7265228B2 (en) 2007-09-04
PT1409467E (pt) 2012-10-24
US9546161B2 (en) 2017-01-17
JP2005502635A (ja) 2005-01-27
US20050222244A1 (en) 2005-10-06
CY2015028I1 (el) 2016-07-27
EP2067775A1 (en) 2009-06-10
US20050009872A1 (en) 2005-01-13
US20120296088A1 (en) 2012-11-22
ES2395463T4 (es) 2013-02-12
US20080058514A1 (en) 2008-03-06
ES2395463T3 (es) 2013-02-15
DK1409467T3 (da) 2012-07-16
EP1409467B1 (en) 2012-04-18
JP2013136618A (ja) 2013-07-11
US8779163B2 (en) 2014-07-15
DK2067775T3 (da) 2012-07-16
EP2266968A3 (en) 2011-05-18
LU92717I2 (fr) 2015-11-24
BR122015016313B8 (pt) 2021-05-25
DK2266968T3 (da) 2013-04-08
US20190322649A1 (en) 2019-10-24
JP4708073B2 (ja) 2011-06-22
ATE554082T1 (de) 2012-05-15

Similar Documents

Publication Publication Date Title
FR15C0036I2 (fr) Un inhibiteur de n-acylsphingosine glycosyltransferase
AU2002348261A1 (en) Diastereoselective synthesis of udp-glucose : n-acylsphingosine glucosyltransferase inhibitors
PT923554E (pt) N-benzilpiperidina e derivados tetrahidropiridina
SE0100902D0 (sv) Compounds
CY1113657T1 (el) Νεα παραγωγα βενζοφαινονης ή αλατα αυτων
ES2188095T3 (es) Carboxamidas heterociclicas.
HK1100037A1 (en) Hiv protease inhibiting sulfonamides
IT1292377B1 (it) Composizioni farmaceutiche a base di prostaglandine
DK0952154T3 (da) N-acyl- og N-aroylaralkylamider
ATE411322T1 (de) 2-thiaquinolizidines als glycosidase- und glycosyltransferase-inhibitoren
DE69432176T2 (de) Verfahren zur herstellung von hiv protease inhibitoren
DK1086114T3 (da) Morfin-6-glucuronidsyntese
CY1113586T1 (el) Ενας αναστολεας ν-ακυλοσφιγγοσινο γλυκοζυλοτρανσφερασης
WO2002058632A3 (en) Primary intermediates for oxidative coloration of hair
WO2001077095A3 (en) Derivatives of alpha-mercaptoacetamide